Prolonged prothrombin time at admission predicts poor clinical outcome in COVID-19 patients

Table 2 Laboratory findings at admission

	Normal Range	Total, n = 213	Survival, n = 178	Death, n = 35	P value, death vs survival
Platelet count × 109/L, median (IQR)	125-350	204 (152-255)	211 (157-264)	169 (117-208)	0.002
Blood coagulation
PT/s, median (IQR)	9-13	12.1 (11.5-12.7)	12 (11.5-12.6)	12.9 (12.0-14.0)	< 0.001
APTT/s, median (IQR)	25-31.3	28.8 (26.5-31.3)	28.6 (26.2-31.2)	29.8 (28.2-32.9)	0.033
TT/s, median (IQR)	14-21	17.3 (16.5-18.3)	17.3 (16.4-18.2)	17.6 (16.7-19.5)	0.099
Fibrinogen in g/L, median (IQR)	2-4	4.10 (3.32-5.12)	4.17 (3.39-5.12)	3.94 (2.49-5.18)	0.294
D-dimer in mg/L, median (IQR)	0-0.55	0.73 (0.40-1.95)	0.62 (0.37-1.63)	2.72 (0.91-17.45)	< 0.001
FDP in mg/L, median (IQR)	0-5	2.72 (1.05-7.05)	2.10 (0.98-5.33)	9.68 (3.20-90.68)	< 0.001
Incidence of coagulation abnormalities
Thrombocytopenia		26 (12.2%)	17 (9.6%)	9 (25.7%)	0.02
Thrombocytosis		10 (4.7%)	10 (5.6%)	0	0.374
PT prolongation		39 (18.8%)	23 (14.6%)	16 (45.7%)	< 0.001
APTT prolongation		56 (26.3%)	41 (23.0%)	15 (42.6)	0.02
APTT shortening		27 (12.7%)	25 (14.0%)	2 (5.7%)	0.265
TT prolongation		8 (3.8%)	3 (1.7%)	5 (14.2%)	0.004
Fibrinogen elevation		105 (49.29%)	89 (50%)	16 (45.7%)	0.708
Fibrinogen reduction		9 (4.7%)	5 (2.8%)	4 (11.4%)	0.043
D-dimer elevation		123 (57.7%)	92 (51.7%)	31 (88.6%)	< 0.001
FDP elevation		66 (31.0%)	47 (26.4%)	19 (54.3%)	0.002

APTT: Activated partial thromboplastin time; COPD: Chronic obstructive pulmonary disease; FDP: Fibrin degradation products; IQR: Interquartile range; PT: Prothrombin time; TT: Thrombin time.